The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

AACR 2017 | Poster 2657/16 – PD-L1 blockade enhances T-cell cytotoxicity against Primary Mediastinal B-Cell Lymphoma

Apr 6, 2017

On Monday 3 rdApril during this year’s American Association for Cancer Research(AACR) annual meeting, a poster ( 2657 / 16) by Tishi Shah, from New York Medical College, Valhalla, NY, et al.titled “PD-L1 blockade enhances T cell cytotoxicity against Primary Mediastinal B-Cell Lymphoma” was presented.

The group aimed to determine if PD-L1 blockade enhances T-cell responses in PD-L1 positive PMBCL.

Key Highlights:

  • Karpas 1106p cells express a low level of PD-L1
  • After treatment with IFNγ for 48 hrs, PD-L1 expression significantly increased
  • Anti-PD-L1 did not significantly affect T-cell mediated inhibition of cell proliferation in Karpas 1106p cells with low PD-L1 expression
  • Anti-PD-L1 and T-cell treatment significantly inhibited cell proliferation in IFNγ treated Karpas 1106p cells versustreatment with T-cells alone (32±18% vs3±3% at E:T = 5:1; P= 0.048)

The poster was concluded by stating that T-cell cytotoxicity was heightened by PD-L1 blockade against PMBCL cells. The blockade was dependent on PD-L1 expression, which can be enhanced by administering IFNγ. Future in vivoNSG xenograft studies are ongoing.

  1. Shah T. et al.PD-L1 blockade enhances T cell cytotoxicity against Primary Mediastinal B-Cell Lymphoma [Poster]. In: Proceedings of the 107th Annual Meetingof the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [ 2657 / 16].